CN104547786B - 治疗高雄激素性痤疮的外用中药组合物及应用 - Google Patents
治疗高雄激素性痤疮的外用中药组合物及应用 Download PDFInfo
- Publication number
- CN104547786B CN104547786B CN201410824540.1A CN201410824540A CN104547786B CN 104547786 B CN104547786 B CN 104547786B CN 201410824540 A CN201410824540 A CN 201410824540A CN 104547786 B CN104547786 B CN 104547786B
- Authority
- CN
- China
- Prior art keywords
- parts
- acne
- excessive androgen
- medicine composition
- leventhal syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 239000003098 androgen Substances 0.000 title claims abstract description 16
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 14
- 206010000496 acne Diseases 0.000 title claims abstract description 14
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims abstract description 22
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 14
- 241000605422 Asparagus asparagoides Species 0.000 claims abstract description 14
- 235000004256 Buglossoides arvense Nutrition 0.000 claims abstract description 14
- 241000218691 Cupressaceae Species 0.000 claims abstract description 14
- 241000118841 Lithospermum incisum Species 0.000 claims abstract description 14
- 241000522620 Scorpio Species 0.000 claims abstract description 14
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 14
- 239000009490 scorpio Substances 0.000 claims abstract description 14
- 206010036049 Polycystic ovaries Diseases 0.000 claims abstract description 13
- 240000001949 Taraxacum officinale Species 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 239000006210 lotion Substances 0.000 abstract description 2
- 238000003908 quality control method Methods 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 239000000341 volatile oil Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 241000270295 Serpentes Species 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000001256 steam distillation Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000008033 biological extinction Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000035175 Oligomenorrhea Diseases 0.000 description 1
- 206010030295 Oligomenorrhoea Diseases 0.000 description 1
- 240000007509 Phytolacca dioica Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 241000245665 Taraxacum Species 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 230000002054 antogonadotrophic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940063189 metrogel Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Insects & Arthropods (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种用于治疗多囊卵巢综合征高雄激素性痤疮的外用中药组合物，由以下重量配比的原料药组成：蒲公英100‑300份，全蝎200‑500份，紫草150‑450份，土茯苓200‑500份，金银花150‑450份，蛇床子100‑300份，黄柏100‑300份。药物的制剂形式为洗剂。本发明药物组合物经临床研究验证了其治疗多囊卵巢综合征高雄激素性痤疮的安全性和有效性，组合物药味少，易于质量控制，同时成本低廉。可在制备用于治疗多囊卵巢综合征高雄激素性痤疮的外用药物中应用。
Description
技术领域
本发明属中药组合物，涉及一种用于治疗多囊卵巢综合征高雄激素性痤疮的外用中药组合物，及其药物用途。
背景技术
多囊卵巢综合征(Polycystic ovary syndrome，PCOS)是育龄妇女中最常见的妇科内分泌疾病。全球范围内5%-10%育龄妇女受此病困扰。PCOS最重要的内分泌特征即为高雄激素血症，卵巢局部和循环雄激素水平高，一方面可以阻碍卵泡的正常生长，造成无排卵或稀发排卵状态，表现为月经周期紊乱，通常为闭经或月经稀发，另一方面可引起多毛、痤疮、皮肤脂溢和／或脱发等临床症状。PCOS是女性高雄性激素血症最常见的原因，而PCOS患者多伴有雄激素升高，其临床表现以迟发性痤疮、多毛为多。目前临床多采用达英-35治疗，达英-35是唯一获准治疗PCOS的避孕药，具有抗雄激素及抗促性腺激素的作用。但由于其避孕药的特性和副作用，临床上并不容易被患者接受。
中医古籍中没有关于“多囊卵巢综合征”病名的记载。本病在古代医家的论著中被描述为“月经后期”、“闭经”、“崩漏”、“不孕症”等。肾为先天之本，主藏精，主导女性生殖器官的发育和生殖功能的形成。胞宫主行月经和孕育胎儿。PCOS常于天癸渐充时起病，在青春期，PCOS的主要表现是月经失调，在育龄期，PCOS的主要表现是不孕症。中医学认为“肺主皮毛”，痤疮发病系素体血热偏盛，饮食不节，外邪侵袭犯肺是致病的重要条件，若湿热夹痰，则会病程缠绵，病情加重。发病机制主要是肺胃积热，循经上熏，血随热行，上壅于胸面，气血郁滞，蕴积肌肤而致。
发明内容
本发明的目的是提供一种用于治疗多囊卵巢综合征高雄激素性痤疮的外用中药组合物，该中药组合物由以下重量配比的原料药组成：蒲公英100-300份，全蝎 200-500份，紫草150-450份，土茯苓200-500份，金银花150-450份，蛇床子100-300份，黄柏100-300份。以上组份的重量以生药计算。每1份可以是1g，也可以是公斤或吨，如果用克为单位，该配方组成可制成药物制剂1000剂。以上组成是按重量作为配比的，在生产时可按照相应比例增大或减小，如大规模生产可以以公斤为单位，或以吨为单位，小规模生产也可以毫克为单位，重量可以增大或减小，但各组成之间的生药材重量配比的比例不变。上述配比的中药组合物，根据需要加入适宜的赋形剂制成适合外用的洗剂。
本发明的另一个目的是提供所述的中药组合物在制备用于治疗多囊卵巢综合征高雄激素性痤疮的外用药物中的应用。
本发明的有益之处是：（1）本发明药物组合物有坚实的中医妇科经典理论支持，组分配比合理；（2）本发明药物组合物临床疗效确切，无毒副作用，使用安全，可在制备用于治疗多囊卵巢综合征高雄激素性痤疮的外用中药组合物中应用；（3）本发明药物组合物药味少，易于质量控制，同时成本低廉。
具体实施方式
本发明通过具体实施例作进一步的说明。
实施例1
药物组合物组成：蒲公英100g，全蝎 200g，紫草150g，土茯苓200g，金银花150g，蛇床子100g，黄柏100g。
制备方法：
（1）取蛇床子加水浸泡2小时，用水蒸汽蒸馏法收集的挥发油饱和水溶液，放入另一容器储存，备用。
（2）取蒲公英，全蝎，紫草，土茯苓，金银花，黄柏粉碎成粗粉，加入上述药渣，加水煎煮2次，每次1小时，合并上煎液，滤过，滤液浓缩至相对浓度为1.03-1.05（50℃）的清膏，放置24小时，加入上述挥发油饱和水溶液，混合均匀，即得。
实施例2
药物组合物组成：蒲公英150g，全蝎 275g，紫草225g，土茯苓275g，金银花225g，蛇床子150g，黄柏150g。
制备方法：
（1）取蛇床子加水浸泡2小时，用水蒸汽蒸馏法收集的挥发油饱和水溶液，放入另一容器储存，备用。
（2）取蒲公英，全蝎，紫草，土茯苓，金银花，黄柏粉碎成粗粉，加入上述药渣，加水煎煮2次，每次1小时，合并上煎液，滤过，滤液浓缩至相对浓度为1.03-1.05（50℃）的清膏，放置24小时，加入上述挥发油饱和水溶液，混合均匀，即得。
实施例3
药物组合物组成：蒲公英200g，全蝎 350g，紫草300g，土茯苓350g，金银花300g，蛇床子200g，黄柏200g。
制备方法：
（1）取蛇床子加水浸泡2小时，用水蒸汽蒸馏法收集的挥发油饱和水溶液，放入另一容器储存，备用。
（2）取蒲公英，全蝎，紫草，土茯苓，金银花，黄柏粉碎成粗粉，加入上述药渣，加水煎煮2次，每次1小时，合并上煎液，滤过，滤液浓缩至相对浓度为1.03-1.05（50℃）的清膏，放置24小时，加入上述挥发油饱和水溶液，混合均匀，即得。
实施例4
药物组合物组成：蒲公英250g，全蝎 425g，紫草375g，土茯苓425g，金银花375g，蛇床子250g，黄柏250g。
制备方法：
（1）取蛇床子加水浸泡2小时，用水蒸汽蒸馏法收集的挥发油饱和水溶液，放入另一容器储存，备用。
（2）取蒲公英，全蝎，紫草，土茯苓，金银花，黄柏粉碎成粗粉，加入上述药渣，加水煎煮2次，每次1小时，合并上煎液，滤过，滤液浓缩至相对浓度为1.03-1.05（50℃）的清膏，放置24小时，加入上述挥发油饱和水溶液，混合均匀，即得。
实施例5
药物组合物组成：蒲公英300g，全蝎 500g，紫草450g，土茯苓500g，金银花450g，蛇床子300g，黄柏300g。
制备方法：
（1）取蛇床子加水浸泡2小时，用水蒸汽蒸馏法收集的挥发油饱和水溶液，放入另一容器储存，备用。
（2）取蒲公英，全蝎，紫草，土茯苓，金银花，黄柏粉碎成粗粉，加入上述药渣，加水煎煮2次，每次1小时，合并上煎液，滤过，滤液浓缩至相对浓度为1.03-1.05（50℃）的清膏，放置24小时，加入上述挥发油饱和水溶液，混合均匀，即得。
实施例6
1．病例收集与分组：
选取57例多囊卵巢综合征高雄激素性痤疮的患者。分为中药治疗组（31例）和西药对照组（26例）。两组患者在年龄、性激素水平、生育情况等方面无显著性差异，具有可比性。排出标准：合并有乳腺、心脑血管、肝、肾和造血系统疾病、精神疾病等其他疾病者；未按规定用药或未能定时随访，无法判断疗效，或资料不全影响疗效判断者；入组前3个月内曾服用或外用各种激素类药物者；患有其他引起痤疮的疾病者。
2．治疗方法
中药治疗组病人使用本药物组合物（组成：蒲公英20g，全蝎 35g，紫草30g，土茯苓35g，金银花30g，蛇床子20g，黄柏20g），每日1剂外洗，每日2次，连续治疗14天。西药对照组病人使用甲硝唑凝胶(江苏圣宝罗药业有限公司生产)，每日1剂外涂，每日2次，连续治疗14天。
3． 疗效观察：参照《中医药新药临床研究指导原则》制定：
痊愈：皮损消退率≥95％，或仅遗留少许色素沉着，症状消失；
显效：皮损大部分消退，消退率70％～95％，症状明显减轻；
有效：皮损部分消退，消退率50％～70％，症状改善；
无效：皮损消退不明显或者加重，消退率＜50％，症状未见变化。
4． 结果：治疗结束后中药治疗组总有效率93.5%，显著高于西药对照组（P<0.05）。治疗过程中未见任何不良反应发生。结果参见表1。
Claims (2)
1.一种治疗多囊卵巢综合征高雄激素性痤疮的外用中药组合物，其特征在于，该中药组合物由以下重量配比的原料药组成：蒲公英100-300份，全蝎 200-500份，紫草150-450份，土茯苓200-500份，金银花150-450份，蛇床子100-300份，黄柏100-300份。
2.根据权利要求1所述的一种治疗多囊卵巢综合征高雄激素性痤疮的外用中药组合物在制备用于治疗多囊卵巢综合征高雄激素性痤疮的外用药物中应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410824540.1A CN104547786B (zh) | 2014-12-26 | 2014-12-26 | 治疗高雄激素性痤疮的外用中药组合物及应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410824540.1A CN104547786B (zh) | 2014-12-26 | 2014-12-26 | 治疗高雄激素性痤疮的外用中药组合物及应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104547786A CN104547786A (zh) | 2015-04-29 |
| CN104547786B true CN104547786B (zh) | 2017-10-31 |
Family
ID=53065557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410824540.1A Active CN104547786B (zh) | 2014-12-26 | 2014-12-26 | 治疗高雄激素性痤疮的外用中药组合物及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104547786B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115957171A (zh) * | 2023-02-23 | 2023-04-14 | 山东健健生物科技有限公司 | 一种治疗皮肤瘙痒的中药化妆水及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101590153A (zh) * | 2008-05-26 | 2009-12-02 | 洪长征 | 复方肤舒液 |
| CN103385971A (zh) * | 2013-06-21 | 2013-11-13 | 潍坊诺达药业有限公司 | 一种治疗痤疮的中药组合物 |
| CN103720865A (zh) * | 2013-12-20 | 2014-04-16 | 张翠月 | 一种治疗痤疮的中药面膜及其制备方法 |
-
2014
- 2014-12-26 CN CN201410824540.1A patent/CN104547786B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101590153A (zh) * | 2008-05-26 | 2009-12-02 | 洪长征 | 复方肤舒液 |
| CN103385971A (zh) * | 2013-06-21 | 2013-11-13 | 潍坊诺达药业有限公司 | 一种治疗痤疮的中药组合物 |
| CN103720865A (zh) * | 2013-12-20 | 2014-04-16 | 张翠月 | 一种治疗痤疮的中药面膜及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 消痤饮治疗寻常痤疮50例;王美德;《安徽中医学院学报》;19940610(第03期);第40页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104547786A (zh) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104107299A (zh) | 一种治疗痛经的中药混合物 | |
| CN101297889B (zh) | 治疗口蹄疫的中药制剂及其制备方法 | |
| CN102120020B (zh) | 一种治疗乳腺增生病和子宫肌瘤的药物组合物及其制备方法 | |
| CN101961449B (zh) | 一种治疗体癣病的中药 | |
| CN104544586A (zh) | 一种防治女性痛经的保健内衣 | |
| CN105012652A (zh) | 一种治疗冠心病的“速效化瘀缓痛散”中药方剂 | |
| CN104547786B (zh) | 治疗高雄激素性痤疮的外用中药组合物及应用 | |
| CN104013817A (zh) | 一种参竹精制剂及其制备方法 | |
| CN104173726B (zh) | 用于产后调理的中药组合物及其制备方法和应用 | |
| CN101461894B (zh) | 一种治疗女性更年期综合症及延缓衰老的药物组合物 | |
| CN102772611A (zh) | 一种中药组合物及其制备方法和应用 | |
| CN102205025B (zh) | 一种治疗痛经和月经不调的中药制剂的制备方法 | |
| CN103610795A (zh) | 一种杜仲降压口服制剂的制备方法 | |
| CN104225016B (zh) | 一种治疗脾胃虚弱型慢性萎缩性胃炎的药物组合物 | |
| CN105687672A (zh) | 一种治疗乳腺炎及乳腺增生的中药组合物及其制备方法 | |
| CN103933154A (zh) | 一种治疗痛风病的中药组合物及其制备方法 | |
| CN103055273B (zh) | 溯源性三原态清瘀解毒养生中药制剂及其制备方法 | |
| CN103239543B (zh) | 一种用于治疗胃下垂的中药有效部位组合物及其制备方法 | |
| CN103690902B (zh) | 用于预防鼻咽癌放化疗放射副反应的中药制剂 | |
| CN103405711A (zh) | 一种治疗脏躁的宁心合剂 | |
| CN103623085B (zh) | 一种治疗风湿性关节炎的中药组合物及其制备方法 | |
| CN101264302A (zh) | 一种中药组合物在制备治疗月经不调和痛经药物中的应用 | |
| CN106511903B (zh) | 辅助利尿剂治疗老年高血压、改善依从性问题的组合物 | |
| CN105288436A (zh) | 一种用于治疗慢性湿疹的药物 | |
| CN103127236B (zh) | 一种治疗风湿性关节炎的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |